PROC: Procaps Group SA Company Value to Net Income

Corporate emblem and logo of Procaps Group (PROC)

Unstable management and accounting errors are undermining shareholder confidence, although demand for products in Latin America remains high. This Procaps Group S.A. (PROC) price chart demonstrates the 4.90 indicator. Procaps Group S.A. (PROC) generates revenue as a CDMO operator while facing FDA pressure and currency fluctuations. Business efficiency relies on robotic gel capsule production lines, which minimize human error and defects.

PROC Procaps Group Corp: Price to Earnings Ratio in the range 07/10/2022 - 12/31/2024
Flagship merchandise of Procaps

Evaluating the valuation of Procaps Group S.A. (PROC) through the lens of market expectations allows for the determination of the premium paid for the business. The issuer's P/E ratio reflects the relationship between current market capitalization and net income, measuring the investment payback period. This chart reveals the gap between the exchange price and actual earnings. High plant utilization and equipment modernization should support profits, thereby stabilizing this metric. Analyzing this metric helps identify the risk of an overvalued asset in a timely manner.

Analysis of competing companies

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|SPRY (ARS Pharmaceuticals Inc) - Market Cap to Net Income|TBPH - Price to Earnings Ratio|Company Value to Net Income AQST (Aquestive Corp)|scpharmaceuticals.com (SCPH) - Price to Earnings Ratio|Market Cap to Earnings Tectonic Therapeutic (TECX)|TNXP (Tonix Pharmaceuticals Holding Corp.) - P/E Multiple|Price to Earnings Ratio SXT China (SXTC)|P/E Multiple EPRX|P/E Multiple BioHarvest Sciences Inc (BHST)|Price to Earnings Ratio eXoZymes Inc EXOZ|ORMP (Oramed) - Market Cap to Net Income|ENTX - Price to Earnings Ratio|Business Payback Period MindWalk Holdings, Inc. HYFT|ABVC (ABVC BioPharma Inc) - Price to Earnings Ratio|Cumberland Corp - Company Value to Net Income|QNTM (Quantum BioPharma Ltd) - P/E Multiple|FGEN - Market Cap to Net Income Ratio|Price to Earnings Ratio Telomir Pharmaceuticals, Inc. (TELO)|RANI (ranitherapeutics.com) - Company Value to Net Income|Price to Earnings Ratio Synergy CHC SNYR|Rallybio Corp (RLYB) - Market Cap to Earnings|LEXX: Price to Earnings Ratio|PULM - P/E Multiple|ftzy.com.cn (PTHL) - Price to Earnings Ratio|Market Cap to Net Income APM (Aptorum Group)|Price to Earnings Ratio LYRA|IBO: Company Value to Net Income|Price to Earnings Ratio TNF Pharmaceuticals (TNFA)|Business Payback Period cbdmd.com|PainReform - Price to Earnings Ratio|Business Payback Period Altamira Therapeutics Ltd (CYTO)|Lipella - P/E Multiple|OPTN - P/E Multiple|PIRS (Pieris Pharmaceuticals) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding|Acelyrin Inc. - Market Cap to Net Income|Price to Earnings Ratio TFF Pharma (TFFP)